Market Research Report
United States Alzheimer's Disease Therapeutics & Diagnostics Market Forecast 2022-2028
|United States Alzheimer's Disease Therapeutics & Diagnostics Market Forecast 2022-2028|
Published: June 21, 2022
Content info: 150 Pages
Delivery time: 2-3 business days
The United States Alzheimer's disease therapeutics & diagnostics market is estimated to progress with a 6.62% CAGR during the forecasting years 2022-2028. The market growth is driven by regular cognitive assessments of senior citizens and the easy availability of relevant drugs.
Alzheimer's is a degenerative disorder that attacks the neurons, affecting thinking, memory loss, behavioral changes, and language skills. The market is anticipated to grow, driven by the vast number of last-stage pipeline and disease-modifying drugs. The United States is the largest player in Alzheimer's disease diagnostics and therapeutics market. Besides, the country also has high expenditure on disease management and high detection rates in primary care settings. According to the US Census Bureau, the population of Americans aged 65+ is expected to surge to 88 million by 2050. These factors are expected to drive the market growth during the forecast years.
Furthermore, the United States Food and Drug Administration has approved various molecules to treat Alzheimer's disease. Also, a combination drug containing Memantine and Donepezil is widely available in the market. The availability of various drugs and molecules to cure the disease produces lucrative opportunities for medicine manufacturers.
Leading players in the market include: GE Healthcare, Baxter International Inc, Amarantus Bioscience Holdings Inc, Cognoptix Inc, Merck & Co Inc, etc.